The set of studies running on Apple's ResearchKit is continuing to expand and improve. Yale School of Medicine and The Icahn School of Medicine at Mount Sinai are the latest to step up their use of the platform, rolling out a new heart condition study and refining an asthma app, respectively.
The FDA has come good on its promise to make its stash of medical device data available publicly.
The latest version alerts users when new information about the shortage of a drug is available.
The acquisition tightens BBK's ties to the team that helped to develop its patient and site engagement mobile app, My Clinical Study Buddy.
With the security of Apple's cloud storage system under scrutiny following reports linking it to the leak of private photographs, the company has barred apps that store health information from using the platform. The stipulation is one of several made by Apple as it tries to expand into healthcare without creating privacy problems or angering regulators.
Over the past year, many tech heavyweights have begun moving into the mHealth sector. Developers got an early look at Google's offering this week, with the search giant releasing a preview version of its APIs for health app developers.
Every year the FDA receives hundreds of Freedom of Information Act requests from biopharma companies for adverse-event data, while others take equally laborious steps to access the information. Now the FDA is opening up its adverse-event data through an application programming interface.
The Merck executive leading the company's digital innovation unit has warned that Boston's startups can still improve, particularly with regards to the degree of scientific rigor applied to their apps.
Beth Noveck's mission has been to apply the transparency and collaboration of the open-source movement to government. Noveck has now left the White House, but the ideas she brought are still percolating through the governmental machine. In 2014, the thinking is set to lead to a new, more open FDA.
The FDA has moved tentatively into the world of smartphones and social media, with its guidance often lagging behind industry expectations and its own activities being grown carefully. These in-house initiatives are now due to gain a new component. The FDA is working on a drug shortages smartphone app.